HDAC inhibitor has been shown to inhibit the CSC stemness by reducing markers NANOG and Survivin expression and, in turn, increasing the sensitivity of laryngeal cancer cells to dihydropyrimidine dehydeogenase (DDP)-based chemotherapy [129]. This evidence concerns the gene HDAC9 and laryngeal carcinoma.